Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ipsen's New Chief Outlines Growth Plans In U.S., Emerging Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Tighter product focus and streamlined R&D will help double sales and triple profits by 2020, says CEO Marc de Garidel.

You may also be interested in...



Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure

As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.

European Price Cuts, Restructuring Charges, Hit France's Ipsen in 2011

Ipsen's restructuring in France and the U.S, and European austerity measures, lead to a series of charges against 2011 profits, but drug sales increase 5% in the year.

In Seeking Focus, Ipsen Turns To Specialty Pharma Model

Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel